Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review

Authors

  • C. Rodrigo,

    Corresponding author
    1. Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
    • Correspondence: Chaturaka Rodrigo, Department of Clinical Medicine, Faculty of Medicine, University of Colombo, 25 Kynsey Road, Colombo 08, Sri Lanka.

      Tel.: +94 71 8130991; fax: +94 112 689188.

      E-mail: chaturaka.rodrigo@gmail.com

    Search for more papers by this author
  • L. Gooneratne

    1. Department of Pathology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
    Search for more papers by this author

  • Manuscript handled by: P. de Moerloose
  • Final decision: F. R. Rosendaal, 31 July 2013

Summary

Primary immune thrombocytopenia is a potentially life-threatening condition. Approximately two-thirds of adult patients do not have a sustained response to steroids (first-line therapy). For these patients, a number of other treatment options exist, such as rituximab, splenectomy, immunosuppressants, and thrombopoietin receptor agonists, but they are costly and have side effects. Dapsone is an inexpensive drug with a well-established safety profile. Unfortunately, this treatment option has not been explored adequately. This review is aimed at analyzing the currently available evidence for the use of dapsone as second-line or third-line therapy in primary immune thrombocytopenia.

Ancillary